GlassScriptPhysician profile
Ashley Arrowood
NPI 1437807583
$5,783.62
in general payments reported to CMS, 2019-2025
28 companies · $2,791 in 2025
The $2,791 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $754 · 2024: $2,038 · 2025: $2,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,550 · Travel and Lodging: $17.79 · Education: $15.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,550.06 |
| Travel and Lodging | $17.79 |
| Education | $15.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $875.01 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $604.23 | 2023-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $594.75 | 2023-2025 | Tarpeyo |
| Amgen INC. | $533.00 | 2023-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $351.38 | 2022-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $339.04 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $291.45 | 2022-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.82 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $241.92 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $203.70 | 2023-2025 | |
| Akebia Therapeutics INC | $188.48 | 2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $179.39 | 2023-2025 | Acthar, Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $144.01 | 2023-2025 | Livtencity |
| Novo Nordisk INC | $138.54 | 2023-2025 | Ozempic, Rivfloza, Rybelsus |
| Pharmacosmos Therapeutics INC. | $138.43 | 2024 | Monoferric |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $120.72 | 2024 | Paradise Renal Denervation System |
| Otsuka America Pharmaceutical, INC. | $105.80 | 2024-2025 | Jynarque |
| Ardelyx, INC. | $88.29 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $69.03 | 2024 | Injectafer |
| Apellis Pharmaceuticals, INC. | $63.95 | 2025 | Empaveli |
| Genzyme Corporation | $55.35 | 2024-2025 | |
| Chiesi USA, INC. | $48.98 | 2025 | Elfabrio |
| Invivyd INC | $34.13 | 2025 | Pemgarda |
| Cormedix INC. | $29.42 | 2024 | Defencath |
| Glaxosmithkline, LLC. | $24.24 | 2025 | Benlysta |
| Kyowa Kirin, INC. | $19.52 | 2024 | Crysvita |
| Nxstage Medical, INC. | $18.27 | 2025 | Nxstage System One |
| Alexion Pharmaceuticals, INC. | $16.77 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Arrowood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.